Venture-Backed Startups

CyrusOne designs and operates data centers with global infrastructure across North America, EMEA, and APAC, providing mission-critical digital infrastructure for large enterprises and hyperscale deployments. The company offers specialized solutions including its Intelliscale platform optimized for AI and high-density computing workloads.

1 investor

Cyscale develops a cloud security platform (CSPM/CNAPP) built around a Security Knowledge Graph that helps security teams identify and prioritize risks across cloud infrastructure, identities, and workloads in multi-cloud environments. It serves organizations of all sizes seeking to manage their cloud security posture and reduce breach risk.

2 investors

CYSIAM provides cyber security services including Cyber Threat Intelligence (CTIaaS), a 24x7 Security Operations Centre, threat operations, and Cyber Incident Response, built around its proprietary CTI platform. It serves public and private sector organisations that treat security and resilience risk seriously, operating a wholly UK-based SOC.

2 investors

Cysiv, acquired by Forescout in July 2022, provided threat detection and response solutions. The company has been integrated into Forescout's platform offerings.

1 investor

CyStellar develops satellite-based geospatial intelligence solutions for insurance risk assessment, delivering real-time risk data through a SaaS platform that combines satellite imagery, weather, and environmental monitoring.

1 investor

cystetic Medicines is a drug development company creating an inhaled dry-powder therapy based on an FDA-approved antifungal compound to treat cystic fibrosis, targeting the roughly 10% of patients not helped by existing modulators. The company focuses on accessible, scalable treatment using aerodynamically engineered nanoparticle delivery.

1 investor

Cytactic provides a platform for cyber crisis readiness and management, enabling organizations to respond faster to cyber incidents and minimize their impact.

2 investors

Cytal presents information about its investors on this page. The page itself does not describe what Cytal builds or the market it serves.

1 investor

Cyta Therapeutics develops polymer-based nanogel therapeutics (IntelliGels) to treat obesity, NASH, type 2 diabetes, and metabolic disorders. The company's lead program, Cyta-001, is a liver-targeted drug delivery system encapsulating a thyroid hormone receptor agonist for metabolic disease management.

1 investor

0 investors

Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Its lead program is being studied in combination with capecitabine and gemcitabine in a Phase 1/2 clinical trial that includes patients with advanced ovarian cancer.

3 investors

Cytek Biosciences develops high-parametric analytical instruments and software that enable scientists at pharmaceutical companies, contract research organizations, and academic institutions to generate and analyze biological datasets. The company serves the life sciences research and drug development sectors.

3 investors

Cytel provides software and biometrics solutions for clinical trial design and delivery in the life sciences industry. The company serves pharmaceutical companies sponsoring clinical trials and their biometrics and biostatistics teams.

2 investors

0 investors

0 investors

0 investors

0 investors

CytoAgents is a clinical-stage biopharmaceutical company developing therapies for the life-threatening symptoms of Cytokine Release Syndrome (CRS), an immune overreaction causing systemic inflammation. It is led by a team of drug development experts and a scientific advisory board focused on immunology and clinical drug development.

1 investor

1 investor

Cytochroma provides genetically diverse iPSC-derived human cell models, high-throughput screening, and phenotypic data (branded "Wet AI") for drug discovery and preclinical validation. It serves pharmaceutical and biotech teams seeking donor-matched, multi-lineage cell panels across diverse populations to support safety, efficacy, and regulatory testing.

1 investor

0 investors

Biopharmaceutical company using molecular biology to produce recombinant derivatives of botulinum neurotoxin for customized applications.

1 investor

Cytodyme builds software for regulatory and quality teams at life science companies to manage post-market reporting, literature reviews, documentation, audits, and submissions. The platform consolidates data from disconnected systems to reduce administrative burden for regulated life science and biotech teams.

1 investor

CytoDyn is a biopharmaceutical company conducting clinical trials, including a Phase 2 colorectal cancer trial.

0 investors